Bahrain vs Jordan: HIV/AIDS deaths averted by antiretroviral therapy
Bahrain
20.62 deaths
in 2024
Jordan
17.47 deaths
in 2024
Bahrain rank
147th
Jordan rank
149th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bahrain
- Jordan
How they compare
Bahrain currently reports 20.62 deaths against 17.47 deaths in Jordan, a difference of 3.15 deaths.
That makes Bahrain's figure about 1.2 times Jordan's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Jordan ahead.
Bahrain ranks 147th and Jordan ranks 149th of 157 countries.
Across the 4 decades both report, Bahrain averaged higher in 1 and Jordan in 2.
Head to head by decade
| Decade | Bahrain | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 3.99 deaths | 5.89 deaths | 1.89 deaths | Jordan |
| 2010s | 7.14 deaths | 11.63 deaths | 4.48 deaths | Jordan |
| 2020s | 17.51 deaths | 16.33 deaths | 1.18 deaths | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bahrain or Jordan?
- Bahrain, at 20.62 deaths against 17.47 deaths in Jordan as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bahrain and Jordan?
- 3.15 deaths, with Bahrain ahead.
- How many years of comparable data are there for Bahrain and Jordan?
- 35 years are reported by both, from 1990 to 2024.
- How do Bahrain and Jordan rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bahrain ranks 147th and Jordan ranks 149th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.